0703Z1-化学生物学
100701-药物化学

化学生物学，药物化学

2004-09--2009-07   中国科学院上海有机化学研究所   博士
2000-09--2004-06   南京大学   学士

   

2015-04~2016-05,哈佛医学院Dana-Farber癌症研究所, Research Scientist
2010-04~2015-03,哈佛医学院Dana-Farber癌症研究所, 博士后
2009-07~2009-12,中国科学院上海有机化学研究所, 助理研究员
2004-09~2009-07,中国科学院上海有机化学研究所, 博士
2000-09~2004-06,南京大学, 学士

   

（ 1 ） 一类细胞程序性坏死抑制剂及其制备方法和用途, 2020, 第 1 作者, 专利号: 202010974345.2

（ 2 ） 一类基于有机砷的II型丙酮酸激酶抑制剂及其制备方法和用途, 2020, 第 1 作者, 专利号: 2020105546116

（ 3 ） 去泛素化酶活性探针及其制备和应用, 2019, 第 1 作者, 专利号: 201911114207.0

（ 4 ） 一类基于有机胂的CDK抑制剂及其制备方 法和用途。, 2019, 第 1 作者, 专利号: 2019109257818.8

（ 5 ） 一类细胞程序性坏死抑制剂及其制备方法和用途, 2019, 第 1 作者, 专利号: 201910425587.3

（ 6 ） DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS, 2017, 第 3 作者, 专利号: PCT/US2017/061004

（ 7 ） HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES, 2017, 第 5 作者, 专利号: PCT/US2017/030116

（ 8 ） JANUS KINASE INHIBITORS AND USES THEREOF, 2015, 第 2 作者, 专利号: PCT/US2015/027312

（ 9 ） HYDROPHOBICALLY TAGGED JANUS KINASE INHIBITORS AND USES THEREOF, 2015, 第 2 作者, 专利号: PCT/US2015/027294

（ 10 ） METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA, 2014, 第 4 作者, 专利号: PCT/US2014/070162

（ 11 ） METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA, 2014, 第 4 作者, 专利号: PCT/US2014/070167

（ 12 ） KINASE INHIBITORS FOR THE TREATMENT OF DISEASE, 2014, 第 3 作者, 专利号: PCT/US2014/046022

   

（1） Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads, JOURNAL OF MEDICINAL CHEMISTRY, 2023, 通讯作者
（2） SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer, ONCOGENE, 2022, 通讯作者
（3） Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer, NATURE CANCER, 2022, 第 13 作者
（4） Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer, JOURNAL OF MEDICINAL CHEMISTRY, 2022, 通讯作者
（5） Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer, CANCER RESEARCH, 2022, 通讯作者
（6） Discovery of a cooperative mode of inhibiting RIPK1 kinase, CELL DISCOVERY, 2021, 通讯作者
（7） Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2, CELL CHEMICAL BIOLOGY, 2021, 通讯作者
（8） The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance., BLOOD, 2021, 第 3 作者
（9） Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma, JOURNAL OF MEDICAL GENETICS, 2020, 第11作者
（10） Identification of a potent and selective covalent Pin1 inhibitor, NATURE CHEMICAL BIOLOGY, 2020, 第 17 作者
（11） Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development, CELL, 2020, 第 7 作者
（12） Modulating TRADD to restore cellular homeostasis and inhibit apoptosis, NATURE, 2020, 第 20 作者
（13） T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment, JOURNAL OF PATHOLOGY, 2020, 第 10 作者
（14） Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities, CELL CHEMICAL BIOLOGY, 2020, 第 2 作者
（15） Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma., J Med Genet., 2019, 第 1 作者
（16） Leveraging compound promiscuity to identify targetable cysteines within the kinome, CELL CHEMICAL BIOLOGY, 2019, 第 7 作者
（17） Discovery and characterization of covalent Pin1 inhibitors targeted to an active site cysteine, CANCER RESEARCH, 2019, 第 14 作者
（18） Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression, CANCER DISCOVERY, 2018, 第 25 作者
（19） A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader, CELL CHEMICAL BIOLOGY, 2018, 通讯作者
（20） Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK), JOURNAL OF MEDICINAL CHEMISTRY, 2018, 第 3 作者
（21） RAS-MAPK reactivation facilitates acquired resistance in FGFR1 -amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade, MOLECULAR CANCER THERAPEUTICS, 2018, 第 8 作者
（22） Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo, ACS CHEMICAL BIOLOGY, 2018, 第 6 作者
（23） When Kinases Meet PROTACs, CHINESE JOURNAL OF CHEMISTRY, 2018, 通讯作者
（24） Synergistic interactions with PI3K inhibition that induce apoptosis, ELIFE, 2017, 第 7 作者
（25） Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 第 1 作者
（26） Structure-guided development of covalent TAK1 inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 第 1 作者
（27） Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD + AML cell growth, PLOS ONE, 2017, 第 3 作者
（28） EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer, CANCER RESEARCH, 2016, 第 3 作者
（29） HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib, BLOOD, 2016, 第 3 作者
（30） Development of Selective Covalent Janus Kinase 3 Inhibitors, JOURNAL OF MEDICINAL CHEMISTRY, 2015, 第 1 作者
（31） DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors, ACS CHEMICAL BIOLOGY, 2015, 第 2 作者
（32） Characterization of DDR2 Inhibitors for the Treatmentof DDR2 Mutated Nonsmall Cell Lung Cancer, ACS CHEMICAL BIOLOGY, 2015, 第 2 作者
（33） Discovery of Type II Inhibitors of TGF beta-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2), JOURNAL OF MEDICINAL CHEMISTRY, 2015, 第 1 作者
（34） EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma, CANCER DISCOVERY, 2015, 第 3 作者
（35） Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors, JOURNAL OF MOLECULAR BIOLOGY, 2014, 第 2 作者
（36） Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 第 1 作者
（37） Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor., ACS Chem Biol., 2014, 第 1 作者
（38） Identification of a small molecule activator of novel PKCs for promoting glucose-dependent insulin secretion, Identification of a small molecule activator of novel PKCs for promoting glucose-dependent insulin secretion, 细胞研究：英文版, 2011, 第 4 作者
（39） Identification of a small molecule activator of novel PKCs for promoting glucose-dependent insulin secretion, Identification of a small molecule activator of novel PKCs for promoting glucose-dependent insulin secretion, CELL RESEARCH, 2011, 第 4 作者
（40） Salinamide A和Sieboldine A的全合成研究, 2009, 第 1 作者
（41） Total synthesis of salinamide A: A potent anti-inflammatory bicyclic depsipeptide, ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 第 1 作者
（42） Total synthesis of salinamide A: A potent anti-inflammatory bicyclic depsipeptide, ANGEW. CHEM.-INT. EDIT., 2008, 第 1 作者

   

（ 1 ） 去泛素化酶USP14的新型小分子抑制剂的研发, 负责人, 国家任务, 2018-01--2021-12
（ 2 ） 神经退行性疾病中细胞死亡机理和干预的研究, 参与, 国家任务, 2016-06--2021-05
（ 3 ） 基于有机砷化合物的新型抗肿瘤靶向药物的研发, 负责人, 地方任务, 2017-07--2019-06
（ 4 ） 新型细胞程序性坏死调控因子与化学干预, 参与, 国家任务, 2019-01--2023-12
（ 5 ） 细胞程序死亡过程中重要蛋白质复合体的动态调 控机制与结构生物学基础, 参与, 地方任务, 2018-12--2021-11
（ 6 ） 新型BACE1抑制剂的研制及其对衰老相关疾病的干预, 负责人, 中国科学院计划, 2020-01--2024-12
（ 7 ） PLpro-RIPK1联合抑制剂对重症新冠肺炎的协同疗效及其机制, 参与, 国家任务, 2022-01--2023-12

（1）Discovery of Novel Organoarsenic Covalent Inhibitors   第十一届全国化学生物学学术会议   2019-11-18
（2）Discovery of Kinase Inhibitors with Novel Inhibitory Mechanisms   2019-10-28
（3）A Shotgun Approach to Inquire Degradable Kinome   2017-10-17